NY‐ESO‐1 protein glycosylated by yeast induces enhanced immune responses
暂无分享,去创建一个
E. Fischer | J. Karbach | V. Cerundolo | K. Odunsi | P. Shrikant | H. Shiku | A. Knuth | F. Neumann | H. Nishikawa | S. Strahl | G. Held | C. Renner | A. Mischo | A. Wadle | S. Kleber | E. Jager | Beate Wullner | Protul A. Shrikant
[1] S. Vlahopoulos,et al. Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin. , 2009, Vaccine.
[2] K. Wittrup,et al. Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles , 2008, Journal of immunotherapy.
[3] J. Irache,et al. Mannose-targeted systems for the delivery of therapeutics , 2008, Expert opinion on drug delivery.
[4] J. Irache,et al. Mannose-targeted systems for the delivery of therapeutics. , 2008, Expert opinion on drug delivery.
[5] J. Beran. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. , 2008, Expert opinion on biological therapy.
[6] S. Levitz,et al. Effect of Differential N-linked and O-linked Mannosylation on Recognition of Fungal Antigens by Dendritic Cells , 2007, PloS one.
[7] Jenny R. Roberts,et al. A Comparison of the Pulmonary Inflammatory Potential of Different Components of Yeast Cell Wall , 2007, Journal of toxicology and environmental health. Part A.
[8] B. Henrissat,et al. Membrane association is a determinant for substrate recognition by PMT4 protein O-mannosyltransferases , 2007, Proceedings of the National Academy of Sciences.
[9] G. Lauer,et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. , 2007, Vaccine.
[10] A. Meyerhans,et al. Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae. , 2006, Vaccine.
[11] Bent K Jakobsen,et al. Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors , 2006, The Journal of Immunology.
[12] D. Jäger,et al. Identification of new NY‐ESO‐1 epitopes recognized by CD4+ T cells and presented by HLA‐DQ B1 03011 , 2006, International journal of cancer.
[13] M. Pfreundschuh,et al. Serological identification of breast cancer‐related antigens from a Saccharomyces cerevisiae surface display library , 2005, International journal of cancer.
[14] Zheng-hong Yuan,et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. , 2005, Vaccine.
[15] I. Davis,et al. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. , 2005, Blood.
[16] M. Schaller,et al. Toll-like receptors as key mediators in innate antifungal immunity. , 2004, Medical mycology.
[17] Yao-Tseng Chen,et al. IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[18] M. Pfreundschuh,et al. Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments , 2004, European journal of immunology.
[19] Julio Aliberti,et al. Turning it on and off: regulation of dendritic cell function in Toxoplasma gondii infection , 2004, Immunological reviews.
[20] Mark Shackleton,et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] T. Luft,et al. NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors , 2004, Clinical Cancer Research.
[22] G. Fink,et al. A Saccharomyces cerevisiae mutant with increased virulence , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Keating,et al. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. , 2003, Drugs.
[24] S. Aamdal,et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. , 2003, European journal of cancer.
[25] Danila Valmori,et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.
[26] V. Kurup,et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. , 2002, Microbes and infection.
[27] Yao-Tseng Chen,et al. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[28] Andreas Suhrbier,et al. Polytope vaccines for the codelivery of multiple CD8T-cell epitopes , 2002, Expert review of vaccines.
[29] P. Rod Dunbar,et al. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols1 , 2002, The Journal of Immunology.
[30] Laurence Zitvogel,et al. Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.
[31] Adrian Ozinsky,et al. Phagocytosis of microbes: complexity in action. , 2002, Annual review of immunology.
[32] Ira Mellman,et al. Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.
[33] J. Sohn,et al. Purification of Soluble β-Glucan with Immune-enhancing Activity from the Cell Wall of Yeast , 2001, Bioscience, biotechnology, and biochemistry.
[34] R. Levy,et al. Linkage of Foreign Carrier Protein to a Self-Tumor Antigen Enhances the Immunogenicity of a Pulsed Dendritic Cell Vaccine1 , 2000, The Journal of Immunology.
[35] Jonathan W. Yewdell,et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.
[36] D. Jäger,et al. Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. , 1999, International journal of cancer.
[37] R. Steinman,et al. Efficient Presentation of Phagocytosed Cellular Fragments on the Major Histocompatibility Complex Class II Products of Dendritic Cells , 1998, The Journal of experimental medicine.
[38] J. Drijfhout,et al. Mannose receptor‐mediated uptake of antigens strongly enhances HLA class II‐restricted antigen presentation by cultured dendritic cells , 1997, European journal of immunology.
[39] M. Bevan,et al. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. , 1997, Blood.
[40] A. Lanzavecchia,et al. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. , 1997, Advances in experimental medicine and biology.
[41] J. Drijfhout,et al. Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells. , 1997, Advances in experimental medicine and biology.
[42] F. Klis,et al. Immobilizing proteins on the surface of yeast cells. , 1996, Trends in biotechnology.
[43] R. Schiestl,et al. Improved method for high efficiency transformation of intact yeast cells. , 1992, Nucleic acids research.